top of page

Design Review 2 for NOAH completed

June 2024

The OxyPrem team is happy to announce that Design Review 2, one of the key milestones en route to MDR CE mark for OxyPrem NOAH, has been successfully completed. 

Third patent granted

June 2024 

The OxyPrem team is glad to announce that a third patent has been granted. It belongs to the Usability block of patent filings. 

This patent follows the first two of our patent portfolio, which have been granted in the USA and China as well as in Europe, respectively. 

Quality-focused patent granted in Europe

May 2024 

The OxyPrem team is proud to announce that an additional patent (scope: quality / durability / longevity) has been granted in Europe. This follows the granting of our first patent in the USA and China.

OxyPrem at ISOTT 2024

May 2024 

Heading for Socorro, New Mexico, Dr. Alexander Kalyanov will participate at the 2024 of the International Society for Oxygen Transport to Tissue (ISOTT). The event takes place from June 9th to 14th. 

We are looking forward to interesting insights and discussions!

OxyPrem at Startupdays 2024

May 2024 

Our CEO Alexander Nitsch will be present at this year's Startupdays (SUD) in Bern on May 30th. We are actively seeking conversations with investors and strategic partners. 

See you in Bern!

OxyPrem supports multinational clinical trial

March 2024 

A consortium of Imperial College (London, UK), Gupta Neonatal Hospital (Hisar, India), and Azienda ospedaliera Luigi Vanvitelli (Naples, Italy) has chosen OxyPrem 1.4 to perform the clinical trial "Physiological responses to intravenous caffeine in neonates with Hypoxic Ischaemic Encephalopathia". 

We are excited to support the medical teams and are looking forward to the collaboration! 

Singapore funding roadshow

February 2024 

In the first week of February, an OxyPrem representative will be in Singapore to meet potential investors and strategic partners. If you are interested in scheduling a meeting, please reach out to us. Thank you!

OxyPrem at MEDICA 2023

November 2023 

Our CEO Alexander Nitsch will visit MEDICA 2023 in Düsseldorf, Germany, on November 15th to meet potential investors, strategic partners, and existing suppliers. The OxyPrem 1.4 tissue oximetry system will be on display at the booth of Phoenix Medical Systems. 

Please reach out to us to arrange a meeting!

OxyPrem selected for UK medtech mission

October 2023

From October 16th to 19th, OxyPrem will be part of the UK Mission for Swiss Medtech Startups, organized jointly by the Swiss and UK administrations. Following a 3-day programme in London, there will also be a hands-on clinical day in Leeds. 

We (Clinical Specialist Paul Hampson, Leeds chapter and CEO Alexander Nitsch, London chapter) are looking forward to attending!

OxyPrem explores crowdlending

September 2023 

The team would be happy to welcome you amongst the backers on this project website!

OxyPrem has launched a crowdlending campaign with our partner swisspeers ag.



Belgium and Netherlands clinical roadshow

September 2023 

In the week starting September 11th, OxyPrem is planning on-site visits to neonatal intensive care units (NICUs) in Belgian and Dutch centers. Please feel free to reach out to us, in case you would like to arrange a meeting or product demonstration.

OxyPrem as double runner-up

May 2023 

Both at the Life Science Zurich Impact Conference and at the Startupdays, OxyPrem finished politely in second place of the pitch battles in our respective verticals.

Thank you to everyone who attended the pitches and to the juries and audiences!




OxyPrem at Arab Health 2023

January 2023

From Jan 30th to Feb 2nd, OxyPrem will co-exhibit at Arab Health 2023 with our partners of Phoenix Medical Systems. We are looking forward to many visitors at booth Z4.F49!                                  

OxyPrem at Neonatal Neurology Symposium

January 2023

From On January 27th, the OxyPrem team will  attend the 24th edition of the Neonatal Neurology Symposium in  Maastricht, The Netherlands, with an own booth and OxyPrem equipment  present on-site.

We are looking forward to present OxyPrem to a highly dedicated and inspiring audience!

OxyPrem at Neocon 2022

December 2022

From Dec 1st to Dec 4th, OxyPrem will  co-exhibit at Neocon 2022 in Calcutta, India. The team is excited to  explore partnerships and get in touch with interested hospital chains  and health centres.

OxyPrem at INFANT symposium in Ireland

November 2022       

OxyPrem sponsors the Research Symposium in  Clinical Trials in Neonatology in Cork, Ireland, on Nov 25th. A full  OxyPrem system will be present at the booth, for all interested  clinicians to get first-hand impressions on the OxyPrem solutions.

OxyPrem at EAPS 2022

October 2022  

Come visit us at our booth no. 43 at EAPS 2022 in Barcelona! We will be present from Oct 6th to Oct 10th and are  looking forward to meet you, have interesting conversations, and show  our solutions to you.

OxyPrem wins 2nd place at Swiss Excellence Award

September 2022

For more details see our LinkedIn profile and the foundation website.

In a close call, OxyPrem finished as the runner-up at the Swiss Excellence Award finals 2022. We are very proud, and thanks to our great team, more successes are hopefully coming soon!



OxyPrem now ISO 13485 certified

August 2022 

For more details see our LinkedIn profile.

The OxyPrem team is proud to announce that our quality management system is now ISO 13485:2016 certified!



OxyPrem obtains CHF 2.2 million grant

January 2022

See SERI's official information HERE. Thank you very much to the EU evaluators and to the great members of SERI for joining us on our path!

OxyPrem has obtained a large SERI-funded EIC Accelerator grant. After a positive EU evaluation of the OxyPrem proposal last year, the Secretariat for Education, Research and Innovation (SERI) decided to cover the grants for the Swiss applicants as direct EU funding was not possible.



OxyPrem onboards EC Representative

January 2022 

Our team is very happy and looking forward to a great collaboration!

OxyPrem has initiated cooperation with EUSwissMed GmbH. EUSwissMed is an authorized EC Representative with long years of experience in the regulatory field.



OxyPrem wins another Seal of Excellence

November 2020 

Once again thank you to the EU!

For the second time, OxyPrem was awarded the EU Seal of Excellence for outstanding projects.



OxyPrem featured in EU publication

August 2020

The European Union has written a feature article on OxyPrem. It is available in six languages via the following link: CLICK.

OxyPrem wins EU Seal of Excellence

May 2020 

Thank you to the EU for this strong encouragement!

OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II). This demonstrates that OxyPrem is among the top science startups in Europe.



OxyPrem 1.4 gets CE mark

September 2019 

Thus, OxyPrem 1.4 may now be used in professional clinical environments. Our entire team is glad to have achieved this big milestone!

The OxyPrem 1.4 tissue oximeter system has obtained the CE mark.



OxyPrem obtains EU support

September 2019 

The OxyPrem application was selected for support under phase I of the SME instrument programme following a thorough review by the European Union.

The European Union is supporting OxyPrem by means of its Horizon 2020 SME instrument. Thank you to the EU for their support!



OxyPrem wins Swiss Indian AIT award

April 2019 

Thank you to all participants and to Venturelab! Read more here and here.

OxyPrem and our friends from Prediva are the Swiss Winners of the 2018/19 Academia-Industry Training (AIT) India programme.




OxyPrem in top 30 of 178 startups

September 2018

This puts OxyPrem on par with the English national team.

OxyPrem has reached the semifinals in the pitching battle of Startup Days 2018.



OxyPrem gets venture kicked

August 2018 

Our team successfully completed the stage I pitch and will soon be heading for the "kickers camp" to prepare for stage II and exchange ideas with other founders. The official announcement is here.

We are now part of Switzerland's well known Venture Kick programme.





bottom of page